FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2481798045> ?p ?o ?g. }

• W2481798045 endingPage "e1002058" @default.
• W2481798045 startingPage "e1002058" @default.
• W2481798045 abstract "There is limited, poorly characterized information about adverse events occurring during maintenance treatment of bipolar disorder. We aimed to determine adverse event rates during treatment with lithium, valproate, olanzapine, and quetiapine.We conducted a propensity score adjusted cohort study using nationally representative United Kingdom electronic health records from January 1, 1995, until December 31, 2013. We included patients who had a diagnosis of bipolar disorder and were prescribed lithium (n = 2148), valproate (n = 1670), olanzapine (n = 1477), or quetiapine (n = 1376) as maintenance mood stabilizer treatment. Adverse outcomes were chronic kidney disease, thyroid disease, hypercalcemia, weight gain, hypertension, type 2 diabetes mellitus, cardiovascular disease, and hepatotoxicity. The propensity score included important demographic, physical health, and mental health predictors of drug treatment allocation. The median duration of drug treatment was 1.48 y (interquartile range 0.64-3.43). Compared to patients prescribed lithium, those taking valproate, olanzapine, and quetiapine had reduced rates of chronic kidney disease stage 3 or more severe, following adjustment for propensity score, age, and calendar year, and accounting for clustering by primary care practice (valproate hazard ratio [HR] 0.56; 95% confidence interval [CI] 0.45-0.69; p < 0.001, olanzapine HR 0.57; 95% CI 0.45-0.71; p < 0.001, quetiapine HR 0.62; 95% CI 0.47-0.80; p < 0.001). Hypothyroidism was reduced in those taking valproate (HR 0.60; 95% CI 0.40-0.89; p = 0.012) and olanzapine (HR 0.48; 95% CI 0.29-0.77; p = 0.003), compared to those taking lithium. Rates of new onset hyperthyroidism (valproate HR 0.24; 95% CI 0.09-0.61; p = 0.003, olanzapine HR 0.31; 95% CI 0.13-0.73; p = 0.007) and hypercalcemia (valproate HR 0.25; 95% CI 0.10-0.60; p = 0.002, olanzapine HR 0.32; 95% CI 0.14-0.76; p = 0.008, quetiapine HR 0.23; 95% CI 0.07-0.73; p = 0.013) were also reduced relative to lithium. However, rates of greater than 15% weight gain on valproate, olanzapine, and quetiapine were higher (valproate HR 1.62; 95% CI 1.31-2.01; p < 0.001, olanzapine HR 1.84; 95% CI 1.47-2.30; p < 0.001, quetiapine HR 1.67; 95% CI 1.24-2.20; p < 0.001) than in individuals prescribed lithium, as were rates of hypertension in the olanzapine treated group (HR 1.41, 95% CI 1.06-1.87; p = 0.017). We found no significant difference in rates of chronic kidney disease stage 4 or more severe, type 2 diabetes mellitus, cardiovascular disease, or hepatotoxicity. Despite estimates being robust following sensitivity analyses, limitations include the potential for residual confounding and ascertainment bias and an inability to examine dosage effects.Lithium use is associated with more renal and endocrine adverse events but less weight gain than commonly used alternative mood stabilizers. Risks need to be offset with the effectiveness and anti-suicidal benefits of lithium and the potential metabolic side effects of alternative treatment options." @default.
• W2481798045 created "2016-08-23" @default.
• W2481798045 creator A5024962501 @default.
• W2481798045 creator A5032352489 @default.
• W2481798045 creator A5047114102 @default.
• W2481798045 creator A5072455307 @default.
• W2481798045 creator A5073245125 @default.
• W2481798045 creator A5074939684 @default.
• W2481798045 date "2016-08-02" @default.
• W2481798045 modified "2023-10-17" @default.
• W2481798045 title "Adverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort Study" @default.
• W2481798045 cites W1492711775 @default.
• W2481798045 cites W1596339956 @default.
• W2481798045 cites W1847436781 @default.
• W2481798045 cites W1935831760 @default.
• W2481798045 cites W1963617120 @default.
• W2481798045 cites W1967161544 @default.
• W2481798045 cites W1968185435 @default.
• W2481798045 cites W1969114959 @default.
• W2481798045 cites W1970411736 @default.
• W2481798045 cites W1977247044 @default.
• W2481798045 cites W1977803503 @default.
• W2481798045 cites W1981346886 @default.
• W2481798045 cites W1983760701 @default.
• W2481798045 cites W1984615306 @default.
• W2481798045 cites W1995631390 @default.
• W2481798045 cites W2000265560 @default.
• W2481798045 cites W2001183362 @default.
• W2481798045 cites W2012476442 @default.
• W2481798045 cites W2016450673 @default.
• W2481798045 cites W2019657225 @default.
• W2481798045 cites W2022425171 @default.
• W2481798045 cites W2027710937 @default.
• W2481798045 cites W2033945449 @default.
• W2481798045 cites W2036054792 @default.
• W2481798045 cites W2036193982 @default.
• W2481798045 cites W2038981426 @default.
• W2481798045 cites W2043524592 @default.
• W2481798045 cites W2043728638 @default.
• W2481798045 cites W2061485367 @default.
• W2481798045 cites W2068953434 @default.
• W2481798045 cites W2074535951 @default.
• W2481798045 cites W2079771827 @default.
• W2481798045 cites W2085580350 @default.
• W2481798045 cites W2086453203 @default.
• W2481798045 cites W2092369059 @default.
• W2481798045 cites W2107176478 @default.
• W2481798045 cites W2121690051 @default.
• W2481798045 cites W2121790486 @default.
• W2481798045 cites W2129938321 @default.
• W2481798045 cites W2135862839 @default.
• W2481798045 cites W2137293399 @default.
• W2481798045 cites W2142912667 @default.
• W2481798045 cites W2144437696 @default.
• W2481798045 cites W2145755811 @default.
• W2481798045 cites W2150291618 @default.
• W2481798045 cites W2155163959 @default.
• W2481798045 cites W2155965977 @default.
• W2481798045 cites W2163692673 @default.
• W2481798045 cites W2164007491 @default.
• W2481798045 cites W2166154813 @default.
• W2481798045 cites W2167854111 @default.
• W2481798045 cites W2171822680 @default.
• W2481798045 cites W2185709237 @default.
• W2481798045 cites W4211069648 @default.
• W2481798045 cites W4239728164 @default.
• W2481798045 cites W871463113 @default.
• W2481798045 doi "https://doi.org/10.1371/journal.pmed.1002058" @default.
• W2481798045 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4970809" @default.
• W2481798045 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27483368" @default.
• W2481798045 hasPublicationYear "2016" @default.
• W2481798045 type Work @default.
• W2481798045 sameAs 2481798045 @default.
• W2481798045 citedByCount "82" @default.
• W2481798045 countsByYear W24817980452016 @default.
• W2481798045 countsByYear W24817980452017 @default.
• W2481798045 countsByYear W24817980452018 @default.
• W2481798045 countsByYear W24817980452019 @default.
• W2481798045 countsByYear W24817980452020 @default.
• W2481798045 countsByYear W24817980452021 @default.
• W2481798045 countsByYear W24817980452022 @default.
• W2481798045 countsByYear W24817980452023 @default.
• W2481798045 crossrefType "journal-article" @default.
• W2481798045 hasAuthorship W2481798045A5024962501 @default.
• W2481798045 hasAuthorship W2481798045A5032352489 @default.
• W2481798045 hasAuthorship W2481798045A5047114102 @default.
• W2481798045 hasAuthorship W2481798045A5072455307 @default.
• W2481798045 hasAuthorship W2481798045A5073245125 @default.
• W2481798045 hasAuthorship W2481798045A5074939684 @default.
• W2481798045 hasBestOaLocation W24817980451 @default.
• W2481798045 hasConcept C118552586 @default.
• W2481798045 hasConcept C126322002 @default.
• W2481798045 hasConcept C197934379 @default.
• W2481798045 hasConcept C207103383 @default.
• W2481798045 hasConcept C2776174506 @default.
• W2481798045 hasConcept C2776412080 @default.
• W2481798045 hasConcept C2776619155 @default.
• W2481798045 hasConcept C2778541603 @default.

• next